The Place of Antipsychotics in the Therapy of Anxiety Disorders and Obsessive-Compulsive Disorders

  title={The Place of Antipsychotics in the Therapy of Anxiety Disorders and Obsessive-Compulsive Disorders},
  author={Baptiste Pignon and Chlo{\'e} Tezenas du Montcel and Louise Carton and Antoine Pelissolo},
  journal={Current Psychiatry Reports},
Purpose of ReviewThe purpose of this review was to assess and present the findings up to this date on the efficacy of antipsychotics in the treatment of generalized anxiety disorders (GAD), social anxiety disorders (SAD), panic disorders (PD), and obsessive-compulsive disorders (OCD), mostly based on published randomized controlled trials (RCTs) or on open-label studies when RCT were lacking.Recent FindingsQuetiapine could be recommended in patients with GAD. The efficacy of aripiprazole in two… 
Obsessive-Compulsive Symptoms in Schizophrenia: an Up-To-Date Review of Literature
OCS appeared reliably as linked to poorer outcomes among patients with schizophrenia, however, the specific clinical value of OCS among other prodromal symptoms of schizophrenia remains unknown.
Comparing the efficacy of ondansetron and granisetron augmentation in treatment-resistant obsessive-compulsive disorder: a randomized double-blind placebo-controlled study.
The benefit of using ondansetron and granisetron as augmenting agents in treatment-resistant obsessive-compulsive disorder is confirmed and needs to be confirmed in further placebo-controlled augmentation studies.
Pharmacogenetics of anxiety disorders
  • O. McGowan
  • Psychology, Biology
    Neuroscience Letters
  • 2020
Adjunctive quetiapine may help fluvoxamine-resistant obsessive-compulsive disorder among female in-patients: A randomized-controlled study
It is indicated that patients with treatment-resistant obsessive-compulsive disorder could benefit more from adding quetiapine, in comparison with aripiprazole, to their ongoing serotonergic medication.
Aripiprazole/Methylphenidate Combination in Children and Adolescents with Disruptive Mood Dysregulation Disorder and Attention-Deficit/Hyperactivity Disorder: An Open-Label Study.
This pilot study showed the tolerability of the aripiprazole/methylphenidate combination by patients with DMDD and ADHD and its efficaciousness for treating clinical symptoms and for improving cognitive function.
Pathological Gambling in a Patient on a Dopamine Agonist.
A patient with RLS seen in a psychiatric setting who presented with suicidal ideation, depression, and PG is reported, as both dopaminergic agents and gabapentinoid drugs have been proven to be effective in treating RLS.
Treating acute anxiety in patients with COVID-19.
A targeted combination of psychopharmacology and psychotherapy (relaxation techniques, breathing exercises, and encouragement) is recommended for the treatment of COVID-19-related emotional distress.
Psychotic, mood and anxiety disorders and venous thromboembolism: a systematic review and meta-analysis.
The risk of VTE among individuals with psychiatric disorders may be explained by hypercoagulability and stasis, with both being related to, and independent of, treatment side-effects.


Is There Room for Second-Generation Antipsychotics in the Pharmacotherapy of Panic Disorder? A Systematic Review Based on PRISMA Guidelines
An updated systematic review of all of the studies that examined the efficacy and tolerability of SGAs in the treatment of PD, with or without other comorbid psychiatric disorders found a general lack of efficacy ofSGAs on panic symptoms.
Role of Atypical Antipsychotics in the Treatment of Generalized Anxiety Disorder
The efficacy and tolerability of atypical antipsychotics as adjunctive therapy and/or monotherapy for individuals with GAD, a currently off-label indication, are reviewed.
An open-label trial of risperidone augmentation for refractory anxiety disorders.
The data suggest that augmentation with low-dose risperidone may be a useful option for patients with PD, SAD, or GAD refractory to adequate initial intervention with antidepressants and/or benzodiazepines.
Guidelines for the pharmacological treatment of anxiety disorders, obsessive–compulsive disorder and posttraumatic stress disorder in primary care
A combination of medication and cognitive behavior/exposure therapy was shown to be a clinically desired treatment strategy and may improve treatment of anxiety disorders, OCD, and PTSD in primary care.
Second Generation Antipsychotic-Induced Obsessive-Compulsive Symptoms in Schizophrenia: A Review of the Experimental Literature
It is suggested that clozapine confers the greatest risk of OCS in schizophrenia, with 20 to 28 % of clozAPine-treated patients experiencing de novo OCS, in addition to 10 to 18 % incurring an exacerbation of pre-existing OCS.
Evidence-based pharmacotherapy of obsessive-compulsive disorder.
  • N. FinebergT. Gale
  • Psychology, Medicine
    The international journal of neuropsychopharmacology
  • 2005
Key questions related to OCD pharmacotherapy are reviewed, synthesizing evidence derived from randomized controlled trials, meta-analyses and consensus guidelines, and SSRIs are the preferred option for long-term treatment in most cases.
Aripiprazole as Augmentation Treatment of Refractory Generalized Anxiety Disorder and Panic Disorder
Preliminary evidence is provided that aripiprazole may be a useful augmentation strategy for individuals with generalized anxiety disorder or panic disorder who show a limited response to initial pharmacotherapy.
Investigational drugs for anxiety in patients with schizophrenia
In spite of ancient positive results and a strong rationale, aripiprazole and related compounds were not in recent clinical trials, and the authors believe that these compounds deserve more attention.
Sulpiride and refractory panic disorder
The effects of 8 weeks of treatment with sulpiride on anxiety symptoms in a population with refractory PD is investigated, suggesting a probable role in treatment of anxiety disorders, even as monotherapy.
Adjunctive risperidone in generalized anxiety disorder: a double-blind, placebo-controlled study.
Study findings suggest that risperidone at low doses may represent a useful tool in the management of symptomatic GAD patients, as demonstrated by greater reductions in HAM-A total scores and psychic anxiety factor scores compared with placebo.